Moderna still plans to deliver 70 million doses of its bivalent COVID-19 booster by the end of the year.
Moderna Inc. (MRNA) said Wednesday that it expects to resolve supply issues for its new COVID-19 booster "in the coming days."
Several media outlets reported this week that a shortage of Moderna's updated booster was the result of the U.S. Food and Drug Administration's ongoing inspection of a plant in Bloomington, Ind., that is operated by Catalent Inc. (CTLT). Moderna and Catalent set up an agreement back in 2020 to manufacture Moderna's COVID-19 vaccines.
The inspection has been completed, and the FDA on Tuesday allowed the 10 delayed batches of vaccine to ship, saying in a statement that "the agency has no concerns with the safety, effectiveness, or quality of these batches."
"We continue to see high demand in certain areas of the country," a Moderna spokesperson told MarketWatch in an email. "We anticipate that these availability constraints will be resolved in the coming days."
The company said it still plans to deliver 70 million doses of its bivalent COVID-19 booster by the end of the year. The updated booster -- called a bivalent shot -- protects against the original strain of the virus as well as the BA.4 and BA.5 subvariants of omicron.
Other COVID-19 news to know:
(END) Dow Jones Newswires
September 22, 2022 07:26 ET (11:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.